임상

HOME > 연구실적 > 임상 > 논문
 
작성일 : 18-05-28 14:13
논문번호 197
논문제목(영문) Angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers in acute ST-segment elevation myocardial infarction patients with diabetes mellitus undergoing percutaneous coronary intervention.
국내외구분 국외 SCI여부 SCI(E)
연구책임자역할 공저자
주저자명 Choi SY, Choi BG
교신저자명 Rha SW
공동저자명 Choi SY, Choi BG, Rha SW, Byun JK, Shim MS, Li H, Mashaly A, Choi CU, Park CG, Seo HS, Oh DJ, Jeong MH, Other Korea Acute Myocardial Infarction Registry (KAMIR) investigators
게제년월일 2017-12-15
ISSN 0167-5273
Impact Factor 6.189
학술지명 International journal of cardiology
서지사항 0집 / 249권 / 0호,   페이지(48 - 54)
요약초록문
(Abstract) 입력		 BACKGROUND:
Diabetes Mellitus (DM) is an important factor of adverse cardiovascular events in acute ST-segment elevation myocardial infarction (STEMI) patients. Renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with improved clinical outcomes, however, there are limited data comparing the effectiveness of two different RAAS inhibitors in STEMI patients with DM undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES).

METHODS:
A total of 3811 eligible STEMI patients with DM were enrolled in Korea Acute Myocardial Infarction Registry (KAMIR). They were stratified into two groups: Angiotensin converting enzyme inhibitors (ACEI) group (n=2691) and angiotensin receptor blockers (ARB) group (n=1120). To adjust baseline confounding factors, we performed propensity score matching (PSM) analysis and evaluated individual and composite major clinical outcomes between the two groups up to 2years.

RESULTS:
After PSM, a total of 1049 well-matched pairs were generated. Baseline clinical, angiographic and procedural characteristics were well-balanced between the two groups. The incidence of death, recurrent myocardial infarction (MI), revascularization and major adverse cardiac events (MACE) were not significantly different between the two groups up to 2years, CONCLUSION: In the present study, ACEI and ARB showed comparable effectiveness and safety on individual and composite clinical outcomes in STEMI patients with DM who underwent successful PCI with DES at least up to 2years.
파일  C197.pdf (566.4K) DATE : 2018-05-28 14:13:52